Biostage, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 7.98 million compared to USD 4.87 million a year ago. Basic loss per share from continuing operations was USD 0.79 compared to USD 0.55 a year ago.
Harvard Apparatus Regenerative Technology Inc.
Equities
HRGN
US09074M2026
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.45 USD | +6.52% | 0.00% | -50.90% |
1st Jan change | Capi. | |
---|---|---|
-50.90% | 35.07M | |
+7.87% | 219B | |
+11.83% | 192B | |
+18.87% | 142B | |
+30.03% | 111B | |
+2.32% | 65.32B | |
+14.15% | 52.45B | |
+2.68% | 49.8B | |
+6.60% | 43.43B | |
+1.85% | 35.95B |
- Stock Market
- Equities
- HRGN Stock
- News Harvard Apparatus Regenerative Technology Inc.
- Biostage, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021